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Oral amiodarone therapy was given to seven patients 
already taking oral f1ecainide regularly. In one addi•
tional patient, administration of f1ecainide was tempo•
rarily discontinued when amiodarone therapy was be•
gun, and then resumed. Amiodarone produced a rise in 
mean dose-adjusted f1ecainide plasma level (trough plasma 
level at steady state/daily dose) from 2.3 ± 0.8 to 3.4 
Flecainide and amiodarone are antiarrhythmic agents with 
dissimilar electrophysiologic and pharmacokinetic proper•
ties (1,2). Each is known to be efficacious in suppressing 
various cardiac arrhythmias and their use in combination 
may, in some cases, have an enhanced antiarrhythmic effect. 
Amiodarone has been reported to have kinetic interactions 
with multiple cardiac and noncardiac drugs, including dig•
oxin, quinidine, procainamide, aprindine, phenytoin and 
warfarin sodium (3). Our findings in eight patients who 
received flecainide and amiodarone in combination suggest 
that an interaction also exists between these two drugs. 
Methods 
Study group. Six men and two women, 40 to 70 years 
old (mean 58), were referred to the Jewish Hospital at Wash•
ington University Arrhythmia Service for management of 
sustained ventricular tachycardia (three patients), aborted 
sudden cardiac death syndrome (three patients), syncope 
(one patient) and recurrent atrial flutter with pre-excitation 
(one patient). Seven patients had coronary artery disease 
and one had rheumatic heart disease. which was treated with 
mitral valve replacement and tricuspid commissurotomy 
several years earlier, and ventricular pre-excitation. All pa•
tients had some degree of left ventricular dysfunction, and 
the left ventricular ejection fraction. measured with radio-
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± 0.9 (ng/ml)/(mg/day) (p < 0.01). Accordingly, the 
mean dose of f1ecainide required to maintain similar 
plasma levels of the drug was one-third lower during 
combined treatment than during therapy with f1ecainide 
alone. This drug interaction must be accounted for when 
amiodarone and f1ecainide are used concomitantly. 
(J Am Coli CardioI1986;7:1127-30) 
nuclide gated ventriculography in seven patients. ranged 
between 21 and 49% (mean 37). Blood urea nitrogen and 
creatinine levels were normal and remained stable through•
out the study in all patients. These patients had all been 
treated with commercially available drugs without satisfac•
tory results. or with intolerable adverse effects. 
Drug administration. Treatment began with oral fle•
cainide in two divided doses daily. at an initial dose of 200 
mg daily. Doses were increased by 100 mg daily at 4 day 
intervals, guided by antiarrhythmic effects, changes in QRS 
complex duration on the 12 lead electrocardiogram, emer•
gence of drug intolerance and plasma drug levels (ng/ml). 
In all patients who had ventricular tachycardia, the decision 
to add amiodarone to the therapeutic regimen was based on 
a partial antiarrhythmic effect from flecainide alone, mea•
sured by electrophysiologic testing performed during steady 
state treatment with maximal tolerated doses. The patient 
with rheumatic heart disease received amiodarone when it 
was observed that flecainide was successful in eliminating 
ventricular pre-excitation, but not atrial flutter. Amiodarone 
administration consisted of a 10 to 14 day oral loading period 
using 1,200 mg daily, divided into three equal doses, after 
which the dose was decreased to 600 mg daily. When amio•
darone was added, flecainide was usually decreased arbi•
trarily by one-third to one-half of the previous dose in an•
ticipation of a possible interaction. This practice was reinforced 
by the observation, in Patient 2, of the development of left 
bundle branch block 4 days after the beginning of treatment 
with amiodarone; a similar change in the electrocardiogram 
had been noted during flecainide monotherapy when the 
plasma level was 920 ng/m!. Because of the inordinately 
prolonged half-life of amiodarone, serial amiodarone plasma 
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Figure 1. Dose-adjusted ftecainide plasma levels measured before 
and during amiodarone therapy in eight patients. 
levels were not systematically measured during this initial 
period of treatment. In one patient (Patient 8) ftecainide was 
temporarily discontinued for 12 days while amiodarone 
treatment (600 mg/day) was begun, and then reintroduced 
in incremental doses. 
Data analysis. Because ftecainide doses were usually 
reduced at the time of amiodarone initiation, a direct com•
parison between ftecainide plasma levels and dose ranges 
before and during amiodarone treatment was not made. In•
stead, all values of ftecainide plasma levels were adjusted 
for the highest steady state daily dose of ftecainide given 
before and during amiodarone therapy. Steady state was 
considered reached when the patient had received a regular 
dose of ftecainide for at least 4 days (2). The dose-adjusted 
measurement was expressed as ftecainide plasma level (ng/ml) 
per daily ftecainide dose (mg). All ftecainide level deter•
minations were performed by either a gas-liquid chro-
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matographic method (4) (Riker Laboratories Inc,) or a high 
performance liquid chromatographic method (5) (Roche 
Biomedical Laboratories, Inc.). All blood specimens were 
drawn immediately before drug administration, Most pa•
tients had conditions that remained stable throughout the 
study and required concomitant therapy with other medi•
cations. This was not controlled for in our study. However, 
no other drug was added to the patients' regimen at the time 
amiodarone therapy was begun. The dose-adjusted plasma 
ftecainide levels recorded in each patient were compared 
before and during amiodarone therapy using the paired Stu•
dent's t test. All results are reported as mean value ± SD. 
Results 
Plasma f1ecainide levels during amiodarone ther•
apy. After the initiation of amiodarone treatment there was 
a rise in the mean dose-adjusted ftecainide plasma level from 
2.3 ± 0.8 before amiodaroneto 3.4 ± 0.9 (ng/ml)/(mg/day) 
during amiodarone treatment (p < 0.01). This rise occurred 
in each patient (Fig. 1). The percent increase in dose-ad•
justed plasma ftecainide levels measured during combination 
therapy ranged from 4 to 191 % (mean = 60 ± 58, p < 
0.03). 
The daily doses of ftecainide associated with steady state 
trough plasma ftecainide levels before and during amioda•
rone treatment are recorded for each patient in Table 1. The 
average daily ftecainide dose, when it was used as a single 
agent, was 325 ± 103 mg, as opposed to 225 ± 113 mg 
when it was used in combination with amiodarone (p < 
0.03). These doses of ftecainide produced average plasma 
levels of 690 ± 173 and 695 ± 220 ng/ml before and 
during amiodarone treatment, respectively (p = 0.96). 
Time course of amiodarone-f1ecainide interaction. 
Sufficient data were not available in each patient to define 
an accurate time course of the drug interaction, particularly 
Table 1. Daily Doses of Flecainide Associated With Steady State Trough Plasma Flecainide Levels Before and During 
Amiodarone Treatment 
Before Amiodarone During Amiodarone 
Flecainide Flecainide 
Plasma Flecainide Number of Plasma Flecainide Number of Number of 
Level Dose Days on Level Dose Days on Days on 
Case (ng/ml) (mg/day) Dose (ng/ml) (mg/day) Dose Amiodarone 
I 790 300 4 550 200 10 14 
2 920 500 4 505 200 114 124 
3 790 200 4 462 100 4 19 
4 696 300 4 597 150 21 32 
5 498 200 4 835 200 4 83 
6 590 400 5 970 400 6 12 
7 418 300 4 610 150 65 72 
8 816 400 150 1034 400 60 51 
Mean ± SD 690 ± 173 325 ± 103 695 ± 220 225 ± 113 
p < 0.03 
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because the daily dose of flecainide was usually reduced at 
the time of initiation of amiodarone treatment to avoid po•
tentially serious adverse side effects. In Patients 6 and 7, 
however, enough information was collected to give an es•
timate of this time course (Fig. 2 and 3). These data suggest 
that the interaction begins early after the onset of amiodarone 
treatment, and may take 2 weeks or more to fully manifest 
itself. Additional studies will be necessary to define this 
time course more accurately. 
Discussion 
Amiodarone-ftecainide interaction and ftecainide 
pharmacokinetics. Combining antiarrhythmic agents is a 
common medical practice, the value of which is supported 
more by theoretical considerations and pragmatic observa•
tions than by systematic trials. Amiodarone is frequently 
combined with other antiarrhythmic agents and is known to 
raise plasma levels of many drugs (3). Thus, the finding of 
an interaction between amiodarone and flecainide was no 
surprise, and because of the high likelihood of toxic com•
plications we chose, in most patients, to reduce the dose of 
flecainide when amiodarone treatment was begun to· avoid 
these complications. In multiple oral dosage studies of 16 
subjects using the superposition method (2), calculated steady 
state plasma levels of flecainide, based on its known phar•
macokinetics, were generally in agreement with the levels 
actually measured. Thus, the plasma pharmacokinetics of 
flecainide were found to be independent of dose or plasma 
concentration, and to be nearly linear with multiple oral 
dosage regimens. This allowed us to quantify, at least ap•
proximately, the interactive process in each patient by cor•
recting the steady state plasma levels for the daily drug 
Figure 2. Patient 6. Rise in f1ecainide plasma level after initiation 
of amiodarone therapy. 
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Figure 3. Patient 7. Rise in f1ecainide plasma level after initiation 
of amiodarone therapy. 
requirements before and during amiodarone ~reatment. 
Whether the pharmacokinetics of flecainide remain linear 
in the presence of amiodarone still needs to be studied. 
Adjustment of ftecainide dosage during combined 
therapy. The potential for serious adverse effects of this 
drug interaction was discussed by Fontaine et al. (6) and 
Leclercq and Coumel (7). These authors, who have treated 
many patients with the two drugs combined, suspected an 
interaction when they noted an increased incidence of car•
diac decompensation, proarrhythmic complications and el•
evation of pacing threshold, adverse effects usually attrib•
uted to flecainide. Their observations led tl].em to 
systematically reduce the dose of flecainide by half the usual 
amounts when combined with amiodarone, although no 
measurements of plasma levels were obtained to confirm 
their clinical impression. Our data suggest that reducing the 
daily dose of flecainide by one-third during combined treat•
ment allows the maintenance of plasma levels in the range 
of those obtained with full doses of monotherapy. However, 
in view of the wide range of individual variations noted 
among our patients, it is imperative to measure serial plasma 
flecainide levels during the initial period of combined ther•
apy to avoid toxic complications or, conversely, underdos•
ing. 
Possible mechanisms of amiodarone-ftecainide inter•
action. The mechanism by which amiodarone elevates fle•
cainide plasma levels has not been elucidated by this study. 
Before embarking on complicated systematic pharmacQki•
netic studies in a group of patients whose hospitalization 
was already lengthy and tedious, we felt an obligation to 
confirm the existence of an interaction. More than one mech•
anism of interaction may be operative; some possibilities 
include a decreased rate of enzymatic biotransformation from 
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altered hepatic function. a decrease in renal elimination, a 
change in drug distribution, competitive protein binding afld 
an increase in enteric absorption. The last two mechanisms 
seem unlikely, because ftecainide is only approximately 40% 
protein bound and becal.\se its enteric absorption is nearly 
complete (2). 
We thank Roy L. McQuinn. PhD and Gordon J. Conard. PhD for reviewmg 
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